BioVie Inc. (NASDAQ:BIVI) Short Interest Down 44.0% in December

BioVie Inc. (NASDAQ:BIVI) was the recipient of a large drop in short interest in December. As of December 31st, there was short interest totalling 1,170,000 shares, a drop of 44.0% from the December 15th total of 2,090,000 shares. Based on an average daily volume of 6,120,000 shares, the short-interest ratio is currently 0.2 days.

BioVie Stock Performance

BIVI stock traded down $0.03 during midday trading on Tuesday, hitting $2.07. 68,692 shares of the stock were exchanged, compared to its average volume of 1,283,313. The stock has a market cap of $36.78 million, a price-to-earnings ratio of -0.18 and a beta of 0.49. BioVie has a fifty-two week low of $1.04 and a fifty-two week high of $33.10. The stock’s 50-day moving average price is $2.63 and its 200-day moving average price is $2.07.

BioVie Company Profile

BioVie Inc, a clinical stage biopharmaceutical company, engages in the discovery, development, and commercialization of drugs for the treatment of chronic debilitating conditions in the United States. Its products pipeline includes BIV201, which completed Phase IIa clinical trial for the treatment of ascites caused due to chronic liver cirrhosis; and NE3107, a potentially selective inhibitor of inflammatory extracellular single-regulated kinase, which is in Phase III clinical trial for the treatment of patients with mild to moderate Alzheimer's disease, as well as Phase 2 clinical trial for the treatment of Parkinson's disease.